SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Merck Begins Phase 3 Trial of Ohtuvayre for COPD Exacerbations

Merck has initiated the Enhance-3 phase 3 trial evaluating Ohtuvayre in chronic obstructive pulmonary disease exacerbations.

MRK

Related stories